nodes	percent_of_prediction	percent_of_DWPC	metapath
Neostigmine—ABCB1—Lisinopril—systemic scleroderma	0.192	0.328	CbGbCtD
Neostigmine—ABCB1—Captopril—systemic scleroderma	0.144	0.246	CbGbCtD
Neostigmine—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.113	0.194	CbGbCtD
Neostigmine—ABCB1—Prednisone—systemic scleroderma	0.0907	0.155	CbGbCtD
Neostigmine—ABCB1—Methotrexate—systemic scleroderma	0.0455	0.0776	CbGbCtD
Neostigmine—Hypotension—Captopril—systemic scleroderma	0.00114	0.00276	CcSEcCtD
Neostigmine—Pruritus—Pentoxifylline—systemic scleroderma	0.00114	0.00276	CcSEcCtD
Neostigmine—Gastrointestinal pain—Mometasone—systemic scleroderma	0.00114	0.00275	CcSEcCtD
Neostigmine—Muscle spasms—Mycophenolic acid—systemic scleroderma	0.00113	0.00274	CcSEcCtD
Neostigmine—Flushing—Lisinopril—systemic scleroderma	0.00113	0.00273	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.00111	0.00269	CcSEcCtD
Neostigmine—Arthralgia—Azathioprine—systemic scleroderma	0.00111	0.00269	CcSEcCtD
Neostigmine—Insomnia—Captopril—systemic scleroderma	0.00111	0.00267	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—systemic scleroderma	0.00111	0.00267	CcSEcCtD
Neostigmine—Diarrhoea—Pentoxifylline—systemic scleroderma	0.0011	0.00267	CcSEcCtD
Neostigmine—Coma—Methotrexate—systemic scleroderma	0.0011	0.00266	CcSEcCtD
Neostigmine—Abdominal pain—Mometasone—systemic scleroderma	0.0011	0.00266	CcSEcCtD
Neostigmine—Mediastinal disorder—Lisinopril—systemic scleroderma	0.0011	0.00265	CcSEcCtD
Neostigmine—Dyspnoea—Captopril—systemic scleroderma	0.00109	0.00263	CcSEcCtD
Neostigmine—Arrhythmia—Lisinopril—systemic scleroderma	0.00109	0.00263	CcSEcCtD
Neostigmine—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00263	CcSEcCtD
Neostigmine—Somnolence—Captopril—systemic scleroderma	0.00109	0.00263	CcSEcCtD
Neostigmine—Agitation—Mycophenolic acid—systemic scleroderma	0.00108	0.00261	CcSEcCtD
Neostigmine—Mental disorder—Lisinopril—systemic scleroderma	0.00107	0.00258	CcSEcCtD
Neostigmine—Dizziness—Pentoxifylline—systemic scleroderma	0.00107	0.00258	CcSEcCtD
Neostigmine—Syncope—Mycophenolic acid—systemic scleroderma	0.00106	0.00255	CcSEcCtD
Neostigmine—Urinary tract disorder—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00255	CcSEcCtD
Neostigmine—Arthralgia—Leflunomide—systemic scleroderma	0.00105	0.00254	CcSEcCtD
Neostigmine—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00253	CcSEcCtD
Neostigmine—Urethral disorder—Mycophenolate mofetil—systemic scleroderma	0.00105	0.00253	CcSEcCtD
Neostigmine—Osteoarthritis—Prednisone—systemic scleroderma	0.00105	0.00253	CcSEcCtD
Neostigmine—Flatulence—Lisinopril—systemic scleroderma	0.00105	0.00253	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00104	0.00252	CcSEcCtD
Neostigmine—Skin disorder—Azathioprine—systemic scleroderma	0.00104	0.0025	CcSEcCtD
Neostigmine—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.00104	0.0025	CcSEcCtD
Neostigmine—Dry mouth—Leflunomide—systemic scleroderma	0.00103	0.00248	CcSEcCtD
Neostigmine—Vomiting—Pentoxifylline—systemic scleroderma	0.00103	0.00248	CcSEcCtD
Neostigmine—Convulsion—Mycophenolic acid—systemic scleroderma	0.00102	0.00247	CcSEcCtD
Neostigmine—Muscle spasms—Lisinopril—systemic scleroderma	0.00102	0.00246	CcSEcCtD
Neostigmine—Rash—Pentoxifylline—systemic scleroderma	0.00102	0.00246	CcSEcCtD
Neostigmine—Dermatitis—Pentoxifylline—systemic scleroderma	0.00102	0.00246	CcSEcCtD
Neostigmine—Headache—Pentoxifylline—systemic scleroderma	0.00101	0.00244	CcSEcCtD
Neostigmine—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00101	0.00243	CcSEcCtD
Neostigmine—Arthralgia—Mycophenolic acid—systemic scleroderma	0.001	0.00242	CcSEcCtD
Neostigmine—Gastrointestinal pain—Captopril—systemic scleroderma	0.001	0.00242	CcSEcCtD
Neostigmine—Asthenia—Mometasone—systemic scleroderma	0.000999	0.00241	CcSEcCtD
Neostigmine—Hypotension—Azathioprine—systemic scleroderma	0.000997	0.00241	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.000996	0.00241	CcSEcCtD
Neostigmine—Cardiac arrest—Prednisone—systemic scleroderma	0.000995	0.0024	CcSEcCtD
Neostigmine—Nervous system disorder—Leflunomide—systemic scleroderma	0.000988	0.00239	CcSEcCtD
Neostigmine—Pruritus—Mometasone—systemic scleroderma	0.000985	0.00238	CcSEcCtD
Neostigmine—Tachycardia—Leflunomide—systemic scleroderma	0.000984	0.00238	CcSEcCtD
Neostigmine—Dry mouth—Mycophenolic acid—systemic scleroderma	0.000981	0.00237	CcSEcCtD
Neostigmine—Skin disorder—Leflunomide—systemic scleroderma	0.000979	0.00236	CcSEcCtD
Neostigmine—Hyperhidrosis—Leflunomide—systemic scleroderma	0.000974	0.00235	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.000972	0.00235	CcSEcCtD
Neostigmine—Abdominal pain—Captopril—systemic scleroderma	0.000967	0.00233	CcSEcCtD
Neostigmine—Mediastinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000963	0.00232	CcSEcCtD
Neostigmine—Nausea—Pentoxifylline—systemic scleroderma	0.000958	0.00231	CcSEcCtD
Neostigmine—Arrhythmia—Mycophenolate mofetil—systemic scleroderma	0.000954	0.0023	CcSEcCtD
Neostigmine—Diarrhoea—Mometasone—systemic scleroderma	0.000953	0.0023	CcSEcCtD
Neostigmine—Syncope—Lisinopril—systemic scleroderma	0.000952	0.0023	CcSEcCtD
Neostigmine—Shock—Mycophenolic acid—systemic scleroderma	0.000946	0.00228	CcSEcCtD
Neostigmine—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.000943	0.00228	CcSEcCtD
Neostigmine—Hypotension—Leflunomide—systemic scleroderma	0.000942	0.00227	CcSEcCtD
Neostigmine—Tachycardia—Mycophenolic acid—systemic scleroderma	0.000938	0.00227	CcSEcCtD
Neostigmine—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.000936	0.00226	CcSEcCtD
Neostigmine—Skin disorder—Mycophenolic acid—systemic scleroderma	0.000934	0.00226	CcSEcCtD
Neostigmine—Loss of consciousness—Lisinopril—systemic scleroderma	0.000933	0.00225	CcSEcCtD
Neostigmine—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00093	0.00224	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000921	0.00223	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.000918	0.00222	CcSEcCtD
Neostigmine—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.000916	0.00221	CcSEcCtD
Neostigmine—Insomnia—Leflunomide—systemic scleroderma	0.000912	0.0022	CcSEcCtD
Neostigmine—Arthralgia—Lisinopril—systemic scleroderma	0.000903	0.00218	CcSEcCtD
Neostigmine—Dyspnoea—Leflunomide—systemic scleroderma	0.000899	0.00217	CcSEcCtD
Neostigmine—Hypotension—Mycophenolic acid—systemic scleroderma	0.000898	0.00217	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000897	0.00217	CcSEcCtD
Neostigmine—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000894	0.00216	CcSEcCtD
Neostigmine—Vomiting—Mometasone—systemic scleroderma	0.000885	0.00214	CcSEcCtD
Neostigmine—Dry mouth—Lisinopril—systemic scleroderma	0.000884	0.00213	CcSEcCtD
Neostigmine—Sweating increased—Prednisone—systemic scleroderma	0.000881	0.00213	CcSEcCtD
Neostigmine—Rash—Mometasone—systemic scleroderma	0.000878	0.00212	CcSEcCtD
Neostigmine—Asthenia—Captopril—systemic scleroderma	0.000877	0.00212	CcSEcCtD
Neostigmine—Dermatitis—Mometasone—systemic scleroderma	0.000877	0.00212	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000876	0.00212	CcSEcCtD
Neostigmine—Osteoarthritis—Methotrexate—systemic scleroderma	0.000875	0.00211	CcSEcCtD
Neostigmine—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000873	0.00211	CcSEcCtD
Neostigmine—Headache—Mometasone—systemic scleroderma	0.000872	0.00211	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00087	0.0021	CcSEcCtD
Neostigmine—Insomnia—Mycophenolic acid—systemic scleroderma	0.00087	0.0021	CcSEcCtD
Neostigmine—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000866	0.00209	CcSEcCtD
Neostigmine—Pruritus—Captopril—systemic scleroderma	0.000865	0.00209	CcSEcCtD
Neostigmine—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000857	0.00207	CcSEcCtD
Neostigmine—Somnolence—Mycophenolic acid—systemic scleroderma	0.000855	0.00206	CcSEcCtD
Neostigmine—Agitation—Mycophenolate mofetil—systemic scleroderma	0.000854	0.00206	CcSEcCtD
Neostigmine—Shock—Lisinopril—systemic scleroderma	0.000852	0.00206	CcSEcCtD
Neostigmine—Tachycardia—Lisinopril—systemic scleroderma	0.000845	0.00204	CcSEcCtD
Neostigmine—Abdominal pain—Azathioprine—systemic scleroderma	0.000844	0.00204	CcSEcCtD
Neostigmine—Skin disorder—Lisinopril—systemic scleroderma	0.000841	0.00203	CcSEcCtD
Neostigmine—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000837	0.00202	CcSEcCtD
Neostigmine—Diarrhoea—Captopril—systemic scleroderma	0.000837	0.00202	CcSEcCtD
Neostigmine—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000834	0.00201	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.00083	0.002	CcSEcCtD
Neostigmine—Nausea—Mometasone—systemic scleroderma	0.000827	0.002	CcSEcCtD
Neostigmine—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000824	0.00199	CcSEcCtD
Neostigmine—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000817	0.00197	CcSEcCtD
Neostigmine—Hypotension—Lisinopril—systemic scleroderma	0.000809	0.00195	CcSEcCtD
Neostigmine—Dizziness—Captopril—systemic scleroderma	0.000809	0.00195	CcSEcCtD
Neostigmine—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000806	0.00195	CcSEcCtD
Neostigmine—Urticaria—Leflunomide—systemic scleroderma	0.000801	0.00193	CcSEcCtD
Neostigmine—Abdominal pain—Leflunomide—systemic scleroderma	0.000797	0.00192	CcSEcCtD
Neostigmine—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000792	0.00191	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000789	0.00191	CcSEcCtD
Neostigmine—Hypersensitivity—Azathioprine—systemic scleroderma	0.000786	0.0019	CcSEcCtD
Neostigmine—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000786	0.0019	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000786	0.0019	CcSEcCtD
Neostigmine—Insomnia—Lisinopril—systemic scleroderma	0.000783	0.00189	CcSEcCtD
Neostigmine—Vomiting—Captopril—systemic scleroderma	0.000778	0.00188	CcSEcCtD
Neostigmine—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000774	0.00187	CcSEcCtD
Neostigmine—Dyspnoea—Lisinopril—systemic scleroderma	0.000772	0.00186	CcSEcCtD
Neostigmine—Rash—Captopril—systemic scleroderma	0.000771	0.00186	CcSEcCtD
Neostigmine—Dermatitis—Captopril—systemic scleroderma	0.00077	0.00186	CcSEcCtD
Neostigmine—Somnolence—Lisinopril—systemic scleroderma	0.00077	0.00186	CcSEcCtD
Neostigmine—Headache—Captopril—systemic scleroderma	0.000766	0.00185	CcSEcCtD
Neostigmine—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00076	0.00184	CcSEcCtD
Neostigmine—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000759	0.00183	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000748	0.00181	CcSEcCtD
Neostigmine—Shock—Mycophenolate mofetil—systemic scleroderma	0.000747	0.0018	CcSEcCtD
Neostigmine—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000744	0.0018	CcSEcCtD
Neostigmine—Hypersensitivity—Leflunomide—systemic scleroderma	0.000743	0.00179	CcSEcCtD
Neostigmine—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000741	0.00179	CcSEcCtD
Neostigmine—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000737	0.00178	CcSEcCtD
Neostigmine—Bradycardia—Prednisone—systemic scleroderma	0.000737	0.00178	CcSEcCtD
Neostigmine—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000734	0.00177	CcSEcCtD
Neostigmine—Diarrhoea—Azathioprine—systemic scleroderma	0.00073	0.00176	CcSEcCtD
Neostigmine—Nausea—Captopril—systemic scleroderma	0.000726	0.00175	CcSEcCtD
Neostigmine—Asthenia—Leflunomide—systemic scleroderma	0.000723	0.00175	CcSEcCtD
Neostigmine—Pruritus—Leflunomide—systemic scleroderma	0.000713	0.00172	CcSEcCtD
Neostigmine—Connective tissue disorder—Prednisone—systemic scleroderma	0.000711	0.00172	CcSEcCtD
Neostigmine—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000709	0.00171	CcSEcCtD
Neostigmine—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000708	0.00171	CcSEcCtD
Neostigmine—Dizziness—Azathioprine—systemic scleroderma	0.000706	0.0017	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000691	0.00167	CcSEcCtD
Neostigmine—Asthenia—Mycophenolic acid—systemic scleroderma	0.00069	0.00167	CcSEcCtD
Neostigmine—Diarrhoea—Leflunomide—systemic scleroderma	0.00069	0.00167	CcSEcCtD
Neostigmine—Urticaria—Lisinopril—systemic scleroderma	0.000688	0.00166	CcSEcCtD
Neostigmine—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000686	0.00166	CcSEcCtD
Neostigmine—Abdominal pain—Lisinopril—systemic scleroderma	0.000685	0.00165	CcSEcCtD
Neostigmine—Pruritus—Mycophenolic acid—systemic scleroderma	0.00068	0.00164	CcSEcCtD
Neostigmine—Vomiting—Azathioprine—systemic scleroderma	0.000679	0.00164	CcSEcCtD
Neostigmine—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000676	0.00163	CcSEcCtD
Neostigmine—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000675	0.00163	CcSEcCtD
Neostigmine—Drowsiness—Methotrexate—systemic scleroderma	0.000674	0.00163	CcSEcCtD
Neostigmine—Rash—Azathioprine—systemic scleroderma	0.000673	0.00163	CcSEcCtD
Neostigmine—Dermatitis—Azathioprine—systemic scleroderma	0.000672	0.00162	CcSEcCtD
Neostigmine—Flushing—Prednisone—systemic scleroderma	0.000672	0.00162	CcSEcCtD
Neostigmine—Headache—Azathioprine—systemic scleroderma	0.000669	0.00161	CcSEcCtD
Neostigmine—Dizziness—Leflunomide—systemic scleroderma	0.000666	0.00161	CcSEcCtD
Neostigmine—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000658	0.00159	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000655	0.00158	CcSEcCtD
Neostigmine—Arrhythmia—Prednisone—systemic scleroderma	0.000647	0.00156	CcSEcCtD
Neostigmine—Vomiting—Leflunomide—systemic scleroderma	0.000641	0.00155	CcSEcCtD
Neostigmine—Hypersensitivity—Lisinopril—systemic scleroderma	0.000638	0.00154	CcSEcCtD
Neostigmine—Dizziness—Mycophenolic acid—systemic scleroderma	0.000636	0.00154	CcSEcCtD
Neostigmine—Rash—Leflunomide—systemic scleroderma	0.000635	0.00153	CcSEcCtD
Neostigmine—Dermatitis—Leflunomide—systemic scleroderma	0.000635	0.00153	CcSEcCtD
Neostigmine—Mental disorder—Prednisone—systemic scleroderma	0.000634	0.00153	CcSEcCtD
Neostigmine—Nausea—Azathioprine—systemic scleroderma	0.000634	0.00153	CcSEcCtD
Neostigmine—Headache—Leflunomide—systemic scleroderma	0.000631	0.00152	CcSEcCtD
Neostigmine—Asthenia—Lisinopril—systemic scleroderma	0.000621	0.0015	CcSEcCtD
Neostigmine—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00062	0.0015	CcSEcCtD
Neostigmine—Pruritus—Lisinopril—systemic scleroderma	0.000613	0.00148	CcSEcCtD
Neostigmine—Vomiting—Mycophenolic acid—systemic scleroderma	0.000611	0.00148	CcSEcCtD
Neostigmine—Rash—Mycophenolic acid—systemic scleroderma	0.000606	0.00146	CcSEcCtD
Neostigmine—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000606	0.00146	CcSEcCtD
Neostigmine—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000603	0.00146	CcSEcCtD
Neostigmine—Headache—Mycophenolic acid—systemic scleroderma	0.000602	0.00145	CcSEcCtD
Neostigmine—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.0006	0.00145	CcSEcCtD
Neostigmine—Nausea—Leflunomide—systemic scleroderma	0.000599	0.00145	CcSEcCtD
Neostigmine—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000598	0.00144	CcSEcCtD
Neostigmine—Urethral disorder—Methotrexate—systemic scleroderma	0.000593	0.00143	CcSEcCtD
Neostigmine—Diarrhoea—Lisinopril—systemic scleroderma	0.000593	0.00143	CcSEcCtD
Neostigmine—Agitation—Prednisone—systemic scleroderma	0.000579	0.0014	CcSEcCtD
Neostigmine—Dizziness—Lisinopril—systemic scleroderma	0.000573	0.00138	CcSEcCtD
Neostigmine—Nausea—Mycophenolic acid—systemic scleroderma	0.000571	0.00138	CcSEcCtD
Neostigmine—Syncope—Prednisone—systemic scleroderma	0.000565	0.00137	CcSEcCtD
Neostigmine—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000559	0.00135	CcSEcCtD
Neostigmine—Loss of consciousness—Prednisone—systemic scleroderma	0.000554	0.00134	CcSEcCtD
Neostigmine—Vomiting—Lisinopril—systemic scleroderma	0.000551	0.00133	CcSEcCtD
Neostigmine—Rash—Lisinopril—systemic scleroderma	0.000546	0.00132	CcSEcCtD
Neostigmine—Convulsion—Prednisone—systemic scleroderma	0.000546	0.00132	CcSEcCtD
Neostigmine—Dermatitis—Lisinopril—systemic scleroderma	0.000546	0.00132	CcSEcCtD
Neostigmine—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000545	0.00132	CcSEcCtD
Neostigmine—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000544	0.00131	CcSEcCtD
Neostigmine—Headache—Lisinopril—systemic scleroderma	0.000543	0.00131	CcSEcCtD
Neostigmine—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000537	0.0013	CcSEcCtD
Neostigmine—Arthralgia—Prednisone—systemic scleroderma	0.000537	0.0013	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000533	0.00129	CcSEcCtD
Neostigmine—Mental disorder—Methotrexate—systemic scleroderma	0.00053	0.00128	CcSEcCtD
Neostigmine—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000519	0.00125	CcSEcCtD
Neostigmine—Nausea—Lisinopril—systemic scleroderma	0.000514	0.00124	CcSEcCtD
Neostigmine—Anaphylactic shock—Prednisone—systemic scleroderma	0.000514	0.00124	CcSEcCtD
Neostigmine—Shock—Prednisone—systemic scleroderma	0.000506	0.00122	CcSEcCtD
Neostigmine—Nervous system disorder—Prednisone—systemic scleroderma	0.000504	0.00122	CcSEcCtD
Neostigmine—Tachycardia—Prednisone—systemic scleroderma	0.000502	0.00121	CcSEcCtD
Neostigmine—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000502	0.00121	CcSEcCtD
Neostigmine—Skin disorder—Prednisone—systemic scleroderma	0.0005	0.00121	CcSEcCtD
Neostigmine—Hyperhidrosis—Prednisone—systemic scleroderma	0.000497	0.0012	CcSEcCtD
Neostigmine—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000482	0.00117	CcSEcCtD
Neostigmine—Rash—Mycophenolate mofetil—systemic scleroderma	0.000478	0.00116	CcSEcCtD
Neostigmine—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000478	0.00115	CcSEcCtD
Neostigmine—Headache—Mycophenolate mofetil—systemic scleroderma	0.000475	0.00115	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000469	0.00113	CcSEcCtD
Neostigmine—Insomnia—Prednisone—systemic scleroderma	0.000465	0.00112	CcSEcCtD
Neostigmine—Convulsion—Methotrexate—systemic scleroderma	0.000456	0.0011	CcSEcCtD
Neostigmine—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000451	0.00109	CcSEcCtD
Neostigmine—Arthralgia—Methotrexate—systemic scleroderma	0.000448	0.00108	CcSEcCtD
Neostigmine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000445	0.00108	CcSEcCtD
Neostigmine—Anaphylactic shock—Methotrexate—systemic scleroderma	0.00043	0.00104	CcSEcCtD
Neostigmine—Nervous system disorder—Methotrexate—systemic scleroderma	0.000422	0.00102	CcSEcCtD
Neostigmine—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000421	0.00102	CcSEcCtD
Neostigmine—Skin disorder—Methotrexate—systemic scleroderma	0.000418	0.00101	CcSEcCtD
Neostigmine—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000416	0.001	CcSEcCtD
Neostigmine—Urticaria—Prednisone—systemic scleroderma	0.000409	0.000987	CcSEcCtD
Neostigmine—Abdominal pain—Prednisone—systemic scleroderma	0.000407	0.000982	CcSEcCtD
Neostigmine—Hypotension—Methotrexate—systemic scleroderma	0.000402	0.00097	CcSEcCtD
Neostigmine—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000392	0.000946	CcSEcCtD
Neostigmine—Insomnia—Methotrexate—systemic scleroderma	0.000389	0.000939	CcSEcCtD
Neostigmine—Dyspnoea—Methotrexate—systemic scleroderma	0.000383	0.000926	CcSEcCtD
Neostigmine—Somnolence—Methotrexate—systemic scleroderma	0.000382	0.000923	CcSEcCtD
Neostigmine—Hypersensitivity—Prednisone—systemic scleroderma	0.000379	0.000915	CcSEcCtD
Neostigmine—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000371	0.000896	CcSEcCtD
Neostigmine—Asthenia—Prednisone—systemic scleroderma	0.000369	0.000891	CcSEcCtD
Neostigmine—Pruritus—Prednisone—systemic scleroderma	0.000364	0.000879	CcSEcCtD
Neostigmine—Diarrhoea—Prednisone—systemic scleroderma	0.000352	0.00085	CcSEcCtD
Neostigmine—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000352	0.000849	CcSEcCtD
Neostigmine—Urticaria—Methotrexate—systemic scleroderma	0.000341	0.000825	CcSEcCtD
Neostigmine—Dizziness—Prednisone—systemic scleroderma	0.00034	0.000821	CcSEcCtD
Neostigmine—Abdominal pain—Methotrexate—systemic scleroderma	0.00034	0.000821	CcSEcCtD
Neostigmine—Vomiting—Prednisone—systemic scleroderma	0.000327	0.00079	CcSEcCtD
Neostigmine—Rash—Prednisone—systemic scleroderma	0.000324	0.000783	CcSEcCtD
Neostigmine—Dermatitis—Prednisone—systemic scleroderma	0.000324	0.000783	CcSEcCtD
Neostigmine—Headache—Prednisone—systemic scleroderma	0.000322	0.000778	CcSEcCtD
Neostigmine—Hypersensitivity—Methotrexate—systemic scleroderma	0.000317	0.000765	CcSEcCtD
Neostigmine—Asthenia—Methotrexate—systemic scleroderma	0.000308	0.000745	CcSEcCtD
Neostigmine—Nausea—Prednisone—systemic scleroderma	0.000306	0.000738	CcSEcCtD
Neostigmine—Pruritus—Methotrexate—systemic scleroderma	0.000304	0.000735	CcSEcCtD
Neostigmine—Diarrhoea—Methotrexate—systemic scleroderma	0.000294	0.00071	CcSEcCtD
Neostigmine—Dizziness—Methotrexate—systemic scleroderma	0.000284	0.000687	CcSEcCtD
Neostigmine—Vomiting—Methotrexate—systemic scleroderma	0.000273	0.00066	CcSEcCtD
Neostigmine—Rash—Methotrexate—systemic scleroderma	0.000271	0.000655	CcSEcCtD
Neostigmine—Dermatitis—Methotrexate—systemic scleroderma	0.000271	0.000654	CcSEcCtD
Neostigmine—Headache—Methotrexate—systemic scleroderma	0.000269	0.00065	CcSEcCtD
Neostigmine—Nausea—Methotrexate—systemic scleroderma	0.000255	0.000617	CcSEcCtD
